Schlenk, R., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H.-J., Zak, P., … Erba, H. (2022). Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML. In ONCOLOGY RESEARCH AND TREATMENT (Vol. 45, pp. 67–67).

Schlenk, R., P. Montesinos, R. Vrhovac, E. Patkowska, H. -. J. Kim, P. Zak, P. -. N. Wang, et al. “Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML.” In ONCOLOGY RESEARCH AND TREATMENT, 45:67–67, 2022.

Schlenk R, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, Zak P, et al. Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML. In: ONCOLOGY RESEARCH AND TREATMENT. 2022. p. 67–67.

Schlenk, R., et al. “Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML.” ONCOLOGY RESEARCH AND TREATMENT, vol. 45, no. SUPPL 2, 2022, pp. 67–67.

Schlenk R, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Mitov T, Hanyok J, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl A, Sekeres M, Dombret H, Amadori S, Wang J, Levis M, Erba H. Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML. ONCOLOGY RESEARCH AND TREATMENT. 2022. p. 67–67.